PATENT CLAIM ANALYSIS

Application Number: 15917191
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "249000"]

Abstract:
In some embodiments, the present invention relates to novel small molecule inhibitors that block the CXCR4-SDF-1 signaling pathway by directly inhibiting the members of the Tec family of kinases, namely Bronc's tyrosine kinese (BTK) and their use in treating disorders in which pathogenesis is mediated by the CXCR4-SDF- 1  signaling pathway.

Claim (Index 4):
A pharmaceutical composition comprising a BTK inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate, thereof for use in treating a disorder associated with overexpression of CXCR4 or dysregulated signaling of CXCR4, and pharmaceutically acceptable carrier, diluent, or excipient.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 90.0
- Lexical Diversity: 1.21277
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15303502', '15101864', '15112968', '15319740', '15906934']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7725353795812048
- 35 USC 102 Novelty (BERT): 0.5344350180028985
- Combined Prediction Score: 0.7487253434233742
- Mean Citation Score: 302.505128
- Max Citation Score: 372.44537
- Similarity Product: 263.4448427987945

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test